Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loyola University autologous dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Loyola University Chicago
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intralymphatic
01
Overview
This is an autologous dendritic cell-based vaccine developed by Loyola University for the treatment of relapsed or refractory advanced ovarian cancer. The vaccine is prepared by harvesting a patient's own monocytes via leukapheresis, which are then differentiated into dendritic cells in a laboratory setting. These dendritic cells are pulsed (loaded) with either autologous tumor lysate or specific tumor-associated peptides, including Mucin 1 (MUC1) and Wilms tumor 1 (WT1), often in conjunction with Keyhole Limpet Hemocyanin (KLH) as an adjuvant. The resulting personalized immunotherapy is injected into the patient's inguinal lymph nodes to prime the immune system to recognize and destroy cancer cells expressing the targeted antigens. The vaccine has been evaluated in Phase 2 clinical trials for patients with advanced ovarian cancer.
- Other names
- DC vaccinationautologous dendritic cell-based vaccinetumor lysate-pulsed dendritic cell vaccineMUC1/WT1 peptide-pulsed dendritic cell vaccine
02
Targets
WT1 (Wilms tumor protein)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on Loyola University autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Loyola University autologous dendritic cell vaccine.